EUVIMEDEUVIMED entdecken
Kohortenstudie

Genital but Not Urinary Tract Infections Associated with SGLT2 Inhibitor Use: A Real-World Cohort Study from Portugal

Helena Martins, João Grilo, Salomé Silva, Sofia Oliveira, Rita Santos, Carolina Moura Pereira, Ana Martinho, Inês Pinto, Cláudia Silva, Ricardo Rodrigues, Ana Cabrita, A I Ferreira und 4 weitere

Portuguese Kidney Journal (PKJ) · 10.05.2026

DOI: 10.71749/pkj.146 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Portuguese Kidney Journal (PKJ), erschienen am 10.05.2026. Verfasst von Helena Martins und 15 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide cardio-renal-metabolic benefits in type 2 diabetes mellitus (T2DM), although concern persists regarding genitourinary infections. This study assessed the incidence of genitourinary infections among patients with T2DM treated with SGLT2i in Portuguese primary care, by infection type, individual agent, and dosage, and evaluated treatment discontinuation and predictors of infection.

Methods

This multicentric retrospective cohort study used electronic health records from Portuguese primary care centers. Adults with T2DM receiving pharmacological treatment between 2019 and 2023 were classified according to SGLT2i use. Genitourinary infection incidence was compared between groups, with infections identified through clinical records, laboratory data, or targeted antimicrobial prescriptions.

Results

A total of 5865 patients were included: 2997 treated with SGLT2i and 2868 with other glucose-lowering agents. Overall genitourinary infections occurred in 9.8% of SGLT2i users and 11.1% of controls (OR 0.87, 95% CI 0.74-1.03; p = 0.109). Urinary tract infections were not increased with SGLT2i: cystitis 6.5% vs 10.1%; OR 0.62, 95% CI 0.52-0.75), pyelonephritis (0.2% vs 0.5%; OR 0.48, 95% CI 0.19-1.18), and prostatitis in male patients (0.4% vs 0.8%; OR 0.53, 95% CI 0.21-1.37). Genital mycotic infections were more frequent with SGLT2i: balanitis in male patients (2.7% vs 0.7%; OR 3.93, 95% CI 1.98-7.81) and vulvovaginal mycotic infection in female patients (3.5% vs 1.5%; OR 2.37, 95% CI 1.42-3.96). Treatment discontinuation due to infection occurred in 1.8%.

Conclusion

SGLT2i were associated with higher genital mycotic infection occurrence, but not with increased urinary tract infection risk, supporting their safety in routine care.

Schlagwörter

genitourinary infectionsurinary tract infectiongenital mycotic infectionsbalanitisvaginal candidiasiscystitispyelonephritisprostatitistype 2 diabetestreatment discontinuation

Zitieren

APA

Martins, H., Grilo, J., Silva, S., Oliveira, S., Santos, R., Pereira, C. M., Martinho, A., Pinto, I., Silva, C., Rodrigues, R., Cabrita, A., Ferreira, A. I., Afonso, L. R., Neves, L., Rodrigues, L., & Rosendo, I. (2026). Genital but Not Urinary Tract Infections Associated with SGLT2 Inhibitor Use: A Real-World Cohort Study from Portugal. Portuguese Kidney Journal (PKJ). https://doi.org/10.71749/pkj.146

Vancouver

Martins H, Grilo J, Silva S, Oliveira S, Santos R, Pereira CM, et al. Genital but Not Urinary Tract Infections Associated with SGLT2 Inhibitor Use: A Real-World Cohort Study from Portugal. Portuguese Kidney Journal (PKJ). 2026. doi:10.71749/pkj.146

BibTeX
@article{Martins2026,
  author = {Martins, Helena and Grilo, João and Silva, Salomé and Oliveira, Sofia and Santos, Rita and Pereira, Carolina Moura and Martinho, Ana and Pinto, Inês and Silva, Cláudia and Rodrigues, Ricardo and Cabrita, Ana and Ferreira, A I and Afonso, Luís Rafael and Neves, Luís and Rodrigues, Luís and Rosendo, Inês},
  title = {Genital but Not Urinary Tract Infections Associated with SGLT2 Inhibitor Use: A Real-World Cohort Study from Portugal},
  journal = {Portuguese Kidney Journal (PKJ)},
  year = {2026},
  doi = {10.71749/pkj.146}
}
Kostenlos starten →